B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

ACVR2B

MOLECULAR TARGET

activin A receptor type 2B

UniProt: Q13705NCBI Gene: 9314 compounds

ACVR2B (activin A receptor type 2B) is targeted by 14 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting ACVR2B

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1alvocidib4.5291
2pazopanib3.6939
3sb 2021903.6437
4tae 6843.4330
5saracatinib3.3327
6jnj 77066213.0921
7lestaurtinib3.0420
8plx 47202.7114
9kw 24492.6413
10ast 4872.5612
11azd 77622.309
12gsk 10709162.208
13Axitinib0.691
14Dasatinib0.691

About ACVR2B as a Drug Target

ACVR2B (activin A receptor type 2B) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 14 compounds with documented ACVR2B interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

ACVR2B inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.